



Preferred Drug List NEW DRUG REVIEW

Proprietary Name: Noxafil®

Common Name: Posaconazole

PDL Category: Antifungals - Assorted

<u>Comparable Products</u>	<u>Preferred Drug List/ Recommended Drug List Status</u>
Sporanox®	Non-Preferred
Vfend®	Preferred

Summary

Indications and Usage: Prophylaxis of invasive Aspergillus and Candida infections in immunocompromised patients 13 years of age and older

Mechanism of Action: Blocks the synthesis of fungal cell wall membranes

Dosage Forms: Suspension; 200mg/5mL

Recommended Dosage: 200mg (5mL) three times daily until patient recovers from neutropenia or immunosuppression

Common Adverse Drug Reactions: Bilirubinemia, elevated hepatic enzymes, nausea, vomiting

Contraindications: Hypersensitivity to any component of the compound, use with ergot alkaloids, use with CYP3A4 substrates (terfenadine, astemizole, cisapride, pimazide, halofantrine, quinidine)

Manufacturer: Schering-Plough Corporation

Analysis: Noxafil® is an antifungal product FDA approved for prophylaxis of Aspergillus infections in patients who are immunocompromised and for treatment of oropharyngeal candidiasis refractory to fluconazole or itraconazole. Thus far, there have been two head-to-head trials comparing efficacy of Noxafil® to other antifungal products currently on the market. One trial was an open-label study comparing Noxafil® to fluconazole or itraconazole; the other was a double-blind study comparing Noxafil® to fluconazole. In both studies, Noxafil® had more favorable outcomes than fluconazole and itraconazole in the prevention of invasive fungal infections in severely immunocompromised patients. Although there are demonstrated clinical advantages of Noxafil® over other treatments available for prevention of invasive Aspergillus infections in immunocompromised patients, other medications appear on the Preferred Drug List as preferred products that are more cost effective than Noxafil®. Additionally, Noxafil® is not recommended to be used as a first line treatment option for oropharyngeal candidiasis.

IME Recommendation:

<input type="checkbox"/> Preferred Drug	<input type="checkbox"/> Recommended Drug
<input checked="" type="checkbox"/> Non-Preferred Drug	<input type="checkbox"/> Non-Recommended Drug
<input type="checkbox"/> Preferred Drug with Conditions	